Sponsor content
213 result(s) found, displaying 31 to 40
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COLUMVI glofitamab (rch) 2.5 mg/2.5 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COLUMVI glofitamab (rch) 10 mg/10 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XOFLUZA baloxavir marboxil 80 mg film-coated tablet blister pack.
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Australian public assessment report (AusPar)Gavreto (pralsetinib) has been approved for the treatment of locally advanced or metastatic RET fusion-positive non-small cell lung cancer.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for POLIVY polatuzumab vedotin 30 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VABYSMO faricimab 120 mg/mL solution for injection vial.
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Prescription medicine decision summaryColumvi (glofitamab) is provisionally approved to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)